MeSH tree: E02.095.465.425
For patients with blood cancers like leukemia and lymphoma, the immunotherapy known as CAR-T cell therapy can be lifesaving. Doctors remove a patient's immune cells, called T cells, engineer them in the lab to better recognize ...
Aug 12, 2026
0
39
Researchers at the USC Viterbi School of Engineering and Keck School of Medicine of USC have engineered a genetic tool that addresses one of the most persistent obstacles in cancer immunotherapy: the physical softness of ...
Aug 12, 2026
0
4
BMJ Group has retracted a data analysis highlighting excess deaths in Europe, North America, Australia and New Zealand following the pandemic. The retraction was prompted by misinformation about the possible reasons for the ...
Aug 11, 2026
0
8
Researchers have developed an implant that could deliver next-generation therapies for ovarian cancer precisely where they are needed while simultaneously monitoring how the disease responds.
Aug 4, 2026
0
10
A little-known group of hard-to-find immune cells could help transform cancer treatment, scientists at the University of Manchester's Cancer Research UK Manchester Institute have found. Their discovery, accepted for publication ...
Aug 4, 2026
0
137
Cleveland Clinic and IBM researchers are using quantum computing to tackle one of the most challenging problems in immuno-oncology: predicting which tumor mutations will trigger an immune response.
Jul 30, 2026
0
5
A Mayo Clinic-led international phase 3 study found that a new immunotherapy helped many patients with an aggressive form of bladder cancer keep their bladder instead of having it surgically removed. The treatment also kept ...
Jul 28, 2026
0
147
Chimeric antigen receptor (CAR)-T cell therapy, which reprograms an individual's immune cells to seek out and destroy certain cancer cells, has revolutionized treatment for blood cancers such as lymphoma. But in some patients, ...
Jul 24, 2026
0
7
Antibodies are like "guided missiles" that find and attack cancer cells, but cancer-causing mutations inside cells have remained a "blind spot" for treatment because antibodies cannot reach them. KAIST researchers have now ...
Jul 24, 2026
0
7
In a phase 1 clinical trial, treatment with the investigational bispecific antibody cevostamab reduced cancer in more than 40% of patients with multiple myeloma, many of whom had already undergone multiple other cancer treatments, ...
Jul 22, 2026
0
9
